ଡାଇହାଇଡ୍ରୋଏର୍ଗୋଟାମାଇନ

ଡାଇହାଇଡ୍ରୋଏର୍ଗୋଟାମାଇନ
Clinical data
Pronunciation	/daɪˌhaɪdroʊ.ɜːrˈɡɒtəmiːn/ dy-HY-droh-ur-GOT-ə-meen
Trade names	D.H.E. 45, Migranal, others
Synonyms	DHE; (5'α)-9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-ergotaman-3',6',18-trione
AHFS/Drugs.com	monograph
MedlinePlus	a603022
data	US FDA: Dihydroergotamine;
Pregnancy; category	US: X ;
Routes of; administration	Nasal spray, SC, IM, IV
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	32% (nasal spray)
Onset of action	Within 5 min (IV), About 30 min (IN)
Elimination half-life	9 hours
Excretion	Bile
Identifiers
	IUPAC name (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide;
ECHA InfoCard	100.007.386
Chemical and physical data
Formula	C33H37N5O5
Molar mass	୫୮୩.୬୯ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]56C[C@@H](C(=O)N[C@]1(C)O[C@]4(O)N(C1=O)[C@@H](Cc2ccccc2)C(=O)N3CCC[C@]34[H])CN(C)[C@]5([H])Cc7c[nH]c8cccc6c78;
	InChI InChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1 ; Key:LUZRJRNZXALNLM-JGRZULCMSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Dihydroergotamine

ଡାଇହାଇଡ୍ରୋଏର୍ଗୋଟାମାଇନ ( DHE ), ମାଇଗ୍ରେନାଲ୍ ଏକ ବେପାର ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅଧକପାଳି, କ୍ଲଷ୍ଟର ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଅତ୍ୟଧିକଔଷଧ ସେବନ ଜନିତ ମୁଣ୍ଡବିନ୍ଧାର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ^[୩] ଅଧକପାଳିଚିକିତ୍ସା କରିବାରେ ଏହାର ଏକ ବିଶେଷ ଲାଭ ଅଛି ।^[୪] ଏହା ନାକ ମାଧ୍ୟମ ସ୍ପ୍ରେ କିମ୍ବା ଇଞ୍ଜେକସନଦ୍ୱାରା ବ୍ୟବହୃତ ହୋଇପାରେ ।^[୨] ଏହି ଔଷଧର ପ୍ରଭାବ ୫ରୁ ୩୦ ମିନିଟ୍ ମଧ୍ୟରେ ଆରମ୍ଭ ହୁଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉଚ୍ଚ ରକ୍ତଚାପ, ମୁହଁ ଲାଲ ଦେଖାଯିବା, ଝାଳ ବୋହିବା, ଅଇ ଲାଗେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମାୟୋକାର୍ଡିଆଲ୍ ଇସକେମିଆ, ଷ୍ଟ୍ରୋକ, ଅନିୟମିତ ହୃତ୍‌ ସ୍ପନ୍ଦନ ଏବଂ ଏର୍ଗୋଟିଜିମ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ, ଯକୃତ କିମ୍ବା ବୃକ୍‌କ ଜନିତ ସମସ୍ୟା କିମ୍ବା ରକ୍ତନଳୀ ରୋଗରେ ବ୍ୟବହାର କରିବାକୁ ସୁପାରିଶ କରାଯାଏ ନାହିଁ ।^[୨] ଏହା ଏର୍ଗୋଟାମାଇନର ଏକ ଉତ୍ପାଦକ ।^[୪] ଏହା ସେରୋଟୋନୋନ, ଡୋପାମିନ ଓ ଆଡ୍ରେନର୍ଜିକ ଅଭିଗ୍ରାହକ ବା ରିସେପ୍ଟରଗୁଡ଼ିକୁ ସକ୍ରିୟ କରିଥାଏ ।^[୪]

ଡାଇହାଇଡ୍ରୋଏର୍ଗୋଟାମାଇନ ପ୍ରଥମେ ୧୯୪୩ ମସିହାରେ ତିଆରି ହୋଇଥିଲା ଏବଂ ସେବେଠାରୁ ସେ ଚିକିତ୍ସା ବ୍ୟବହାରରେ ଅଛି । ^[୨] ^[୪] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଏକ ମାତ୍ରା ଇଞ୍ଜେକସନର ମୂଲ୍ୟ ପ୍ରାୟ ୪୫ ଡଲାର ଏବଂ ୨୦୨୧ ସୁଦ୍ଧା ନାକ ସ୍ପ୍ରେର ମୂଲ୍ୟ ୩୭୦ ଡଲାର ରହିଛି ।^[୫] ^[୬] ୨୦୧୦ ଦଶକଠାରୁ ଏହା ଟ୍ରିପଟାନ୍ସ ଅପେକ୍ଷା କମ୍ ବ୍ୟବହୃତ ହେଉଛି ।^[୭]

ଆଧାର

1 2 3 4 5 6 "Dihydroergotamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 March 2021. Retrieved 23 July 2021.
1 2 3 4 Levin, Morris (8 May 2008). Comprehensive Review of Headache Medicine (in ଇଂରାଜୀ). Oxford University Press, USA. p. 217. ISBN 978-0-19-536673-0. Archived from the original on 28 August 2021. Retrieved 23 July 2021.
↑ Shafqat, R; Flores-Montanez, Y; Delbono, V; Nahas, SJ (2020). "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations". Journal of pain research. 13: 859–864. doi:10.2147/JPR.S203650. PMID 32431533.{{cite journal}}: CS1 maint: unflagged free DOI (link)
1 2 3 4 Silberstein, SD; Shrewsbury, SB; Hoekman, J (January 2020). "Dihydroergotamine (DHE) - Then and Now: A Narrative Review". Headache. 60 (1): 40–57. doi:10.1111/head.13700. PMID 31737909.
1 2 "Dihydroergotamine Mesylate Prices and Dihydroergotamine Mesylate Coupons - GoodRx". GoodRx. Retrieved 23 July 2021.
↑ "Dihydroergotamine Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 7 August 2019. Retrieved 23 July 2021.
↑ Singh, Mamta; Bhatia, Rohit (April 2011). Emergencies in Neurology (in ଇଂରାଜୀ). Byword Books Private Limited. p. 155. ISBN 978-81-8193-067-5. Archived from the original on 2021-08-29. Retrieved 2021-07-23.

[AHFS2021-1] 1 2 3 4 5 6 "Dihydroergotamine Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 6 March 2021. Retrieved 23 July 2021.

[Lev2008-2] 1 2 3 4 Levin, Morris (8 May 2008). Comprehensive Review of Headache Medicine (in ଇଂରାଜୀ). Oxford University Press, USA. p. 217. ISBN 978-0-19-536673-0. Archived from the original on 28 August 2021. Retrieved 23 July 2021.

[Sha2020-3] Shafqat, R; Flores-Montanez, Y; Delbono, V; Nahas, SJ (2020). "Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations". Journal of pain research. 13: 859–864. doi:10.2147/JPR.S203650. PMID 32431533.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[Sil2020-4] 1 2 3 4 Silberstein, SD; Shrewsbury, SB; Hoekman, J (January 2020). "Dihydroergotamine (DHE) - Then and Now: A Narrative Review". Headache. 60 (1): 40–57. doi:10.1111/head.13700. PMID 31737909.

[GX2021-5] 1 2 "Dihydroergotamine Mesylate Prices and Dihydroergotamine Mesylate Coupons - GoodRx". GoodRx. Retrieved 23 July 2021.

[6] "Dihydroergotamine Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 7 August 2019. Retrieved 23 July 2021.

[7] Singh, Mamta; Bhatia, Rohit (April 2011). Emergencies in Neurology (in ଇଂରାଜୀ). Byword Books Private Limited. p. 155. ISBN 978-81-8193-067-5. Archived from the original on 2021-08-29. Retrieved 2021-07-23.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]